#Netherlands #Amsterdam #Norgine #Mavorixafor #WHIM syndrome

Norgine's Groundbreaking Step for WHIM Syndrome Treatment

Norgine B.V., a leading European pharmaceutical company, has expressed its satisfaction with the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation pertains to the market authorization for mavorixafor, designed for patients aged 12 and older who are suffering from the ultra-rare WHIM syndrome, which stands for Warts, Hypogammaglobulinemia, Infections, and Myelokathexis.

What is WHIM Syndrome?

WHIM syndrome is characterized by a unique combination of symptoms that can lead to significant health issues, including chronic neutropenia, which is a shortage of neutrophils—important components of the immune system. The syndrome occurs due to a malfunction of the CXCR4 chemokine receptor, affecting the mobility of white blood cells from bone marrow into the bloodstream, thus causing recurrent and severe infections.

Currently, patients diagnosed with WHIM syndrome do not have any approved treatment options, making this recent recommendation a major breakthrough. The CHMP has deemed this application for mavorixafor as exceptional, permitting marketing authorization under circumstances that would otherwise be unavailable due to the complexities surrounding such a rare condition.

The next step will be for the European Commission to review this recommendation, and a final decision is expected in the second quarter of 2026. Norgine’s commitment to this project is unwavering. Janneke van der Kamp, Norgine’s CEO, stated this advancement as a critical regulatory step for WHIM patients in Europe. She highlighted Norgine's extensive experience in providing specialized medicines in Europe, Australia, and New Zealand, emphasizing the company’s dedication to innovation in the healthcare space.

The Clinical Trial Results

The positive CHMP opinion was influenced by results from a pivotal Phase 3 clinical trial named 4WHIM, which was a multicenter, randomized, double-blind, placebo-controlled study lasting for 52 weeks. This clinical study assessed the efficacy and safety of mavorixafor in 31 patients aged 12 years and older diagnosed with WHIM syndrome. These results were paramount in solidifying the case for mavorixafor as an effective treatment option.

In January 2025, Norgine and X4 Pharmaceuticals entered a licensing agreement, setting the stage for Norgine to be responsible for the commercialization of mavorixafor in Europe, Australia, and New Zealand upon regulatory approval. As per this agreement, Norgine will manage all market access and marketing activities, while X4 will supply the necessary drug product.

About Mavorixafor

Mavorixafor is a selective antagonist of the CXCR4 receptor, which plays a critical role in immune response regulation. By binding to this receptor, mavorixafor prevents the interaction with its natural ligand, CXCL12, thus facilitating the mobilization of white blood cells. Currently, the drug is marketed under the name XOLREMDI® in the United States.

Norgine's Mission

Norgine is a mid-sized European pharmaceutical company that employs around 1,500 people and generates an annual revenue of approximately $650 million. Their core mission focuses on providing life-changing medicines across a spectrum of conditions—from common issues such as constipation to rare, severe diseases like pediatric cancer. Norgine is driven by the goal to address unmet medical needs and is guided by the trust of healthcare professionals and patients, ensuring they deliver innovations that can transform lives.

The approval of mavorixafor for treating WHIM syndrome marks not just a significant development in the therapeutic landscape for this rare disease but also represents an important milestone in Norgine's journey of commitment to healthcare advancements. This positive CHMP opinion showcases the organization's capacity to influence the future of medical treatments, one patient at a time.